Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation

被引:0
|
作者
Bohi, Flurina [1 ,2 ]
Hottiger, Michael O. [1 ]
机构
[1] Univ Zurich, Dept Mol Mech Dis, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Life Sci Zurich Grad Sch, Canc Biol Ph D Program, CH-8057 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
PARP1; PARP inhibitors; immunomodulation; macrophages; T cells; cancer therapy; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE-1; EXPRESSION; EFFICACY; CELLS; COACTIVATION; RESISTANCE; OLAPARIB; TUMORS;
D O I
10.3390/biomedicines12071617
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The emergence of PARP inhibitors as a therapeutic strategy for tumors with high genomic instability, particularly those harboring BRCA mutations, has advanced cancer treatment. However, recent advances have illuminated a multifaceted role of PARP1 beyond its canonical function in DNA damage repair. This review explores the expanding roles of PARP1, highlighting its crucial interplay with the immune system during tumorigenesis. We discuss PARP1's immunomodulatory effects in macrophages and T cells, with a particular focus on cytokine expression. Understanding these immunomodulatory roles of PARP1 not only holds promise for enhancing the efficacy of PARP inhibitors in cancer therapy but also paves the way for novel treatment regimens targeting immune-mediated inflammatory diseases.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
    Peng, Xiaopeng
    Pan, Wanyi
    Jiang, Feng
    Chen, Weiming
    Qi, Zetao
    Peng, Weijie
    Chen, Jianjun
    PHARMACOLOGICAL RESEARCH, 2022, 186
  • [2] The role of PARP1 in the DNA damage response and its application in tumor therapy
    Zhifeng Wang
    Fengli Wang
    Tieshan Tang
    Caixia Guo
    Frontiers of Medicine, 2012, 6 (2) : 156 - 164
  • [3] PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
    van Beek, Lotte
    McClay, Eilis
    Patel, Saleha
    Schimpl, Marianne
    Spagnolo, Laura
    Maia de Oliveira, Taiana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
  • [4] Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells
    Jiang, Jiuliang
    Yang, Pingping
    Xu, Xinyu
    Yuan, Huixiong
    Zhu, Haitao
    ANTI-CANCER DRUGS, 2024, 35 (09) : 789 - 805
  • [5] Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective
    Zhang, Jiahui
    Zhang, Jin
    Li, Hua
    Chen, Lixia
    Yao, Dahong
    DRUG DISCOVERY TODAY, 2023, 28 (07)
  • [6] PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
    Kim, Chiho
    Wang, Xu-Dong
    Yu, Yonghao
    ELIFE, 2020, 9
  • [7] SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors
    Lu, Zhen
    Mao, Wequn
    Pang, Lan
    Santiago-O'Farrill, Janice M.
    Yang, Haling
    Ahmed, Ahmed
    Vankayalapati, Hariprasad
    Bast, Robert C.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
    Shao, Zhengping
    Lee, Brian J.
    Rouleau-Turcotte, Elise
    Langelier, Marie-France
    Lin, Xiaohui
    Estes, Verna M.
    Pascal, John M.
    Zha, Shan
    NUCLEIC ACIDS RESEARCH, 2020, 48 (17) : 9694 - 9709
  • [9] PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage
    Mahe, Etienne
    Akhter, Ariz
    Le, Anne
    Street, Lelsey
    Pournaziri, Payam
    Kosari, Farid
    Shabani-Rad, Meer-Taher
    Stewart, Douglas
    Mansoor, Adnan
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (04) : 159 - 165
  • [10] PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective
    Wisnik, Ewelina
    Ryksa, Marcin
    Koter-Michalak, Maria
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2016, 70